ArticleScience progress
Association between estimated pulse wave velocity and the risk of mortality in patients with sepsis patients: A cohort study.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveSepsis remains a primary contributor to mortality among critically ill individuals, and the assessment of vascular stiffness, indicated by estimated pulse wave velocity (ePWV), could offer insights into patient outcomes. This retrospective cohort study examines the correlation between ePWV levels and all-cause mortality in individuals with sepsis.MethodsA total of 22,166 sepsis patients from the MIMIC-IV database were included. Cox regression analysis, restricted cubic spline (RCS) analysis, and subgroup analyses were conducted to evaluate the association between ePWV and 30-day and 365-day mortality.ResultsThe 30-day and 365-day mortality rates were 18.28% and 32.93%, respectively. Compared to the first quartile (Q1), patients in the highest ePWV quartile (Q4) had a 92% higher risk of 30-day mortality (HR: 1.92, 95% CI: 1.73-2.13,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.